explore -WSS

explore

author：focus 2025-09-14 21:45:34 - browse：18

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： US judge blocks portions of new Florida elections law

WSS

The White House hikes tariffs on plastic syringes made in China

4 dead, 2 in stable condition in Philadelphia shooting: Police

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

1 dead, 9 hurt in July 4th fireworks explosion

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Ripples from Flovent's discontinuation is killing children with asthma

focus

explore

entertainment

Medical records are filled with copy

STAT reporters are Pulitzer Prize finalists for investigative reporting

Peter Hotez and the public health issue of online harassment

Galapagos to make CAR

Drug repurposing or repositioning? The language matters

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

Cancer drug shortages should be causing more outrage

What a koala virus tells us about the human genome

Moonlake's readout produced a cash windfall. Risks remain

Obesity drug from Roche shows promise in early study

focus

Galapagos to make CAR

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

Noem? Reynolds? A very early look at the Republican 'veepstakes'

EU climate chief is concerned over the expansion of the coal industry in China

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

What a koala virus tells us about the human genome

hotspot

explore

knowledge

leisure time